Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hikma PharmaceuticalsHKMPF 82 EV-to-EBIT is 9.47 as of Aug. 06, 2026, which is 34% below its 10-year median of 14.28. GuruFocus rates HKMPF with a GF Score™ of 82/100 and a GF Value™ of $28.58 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 688 Drug Manufacturers companies, Hikma Pharmaceuticals ranks better than 71.51% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Hikma Pharmaceuticals's Enterprise Value for the quarter that ended in Jun. 2026 was $6,082 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hikma Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $611 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hikma Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Hikma Pharmaceuticals's EV-to-EBIT falls into.
Hikma Pharmaceuticals's current Enterprise Value is $5,789 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hikma Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $611 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hikma Pharmaceuticals (HKMPF) has a EV-to-EBIT of 9.47 as of Aug. 06, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Hikma Pharmaceuticals and its competitors. This is 34% below median its historical median of 14.28. According to the industry distribution chart, Hikma Pharmaceuticals ranks #196 out of 688 companies in the Drug Manufacturers industry, placing it in the top 28.5%.
Is Hikma Pharmaceuticals' EV-to-EBIT too high?
Hikma Pharmaceuticals' current EV-to-EBIT of 9.47 is 34% below median its 10-year median of 14.28. The Drug Manufacturers industry median EV-to-EBIT is 15.55. Hikma Pharmaceuticals' value of 9.47 is 39.1% below this industry median. Based on the distribution chart, Hikma Pharmaceuticals ranks #196 out of 688 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hikma Pharmaceuticals has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hikma Pharmaceuticals ranks #196 out of 688 companies for EV-to-EBIT. This puts Hikma Pharmaceuticals in the upper half of its industry. The industry median EV-to-EBIT is 15.55. Hikma Pharmaceuticals' value of 9.47 is 39.1% below this benchmark. While the company's 10-year median is 14.28 vs. the industry median of 15.55, Hikma Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.55, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hikma Pharmaceuticals's current EV-to-EBIT of 9.47 is 39.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Hikma Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hikma Pharmaceuticals's current EV-to-EBIT is 9.47, which is 34% below median its own 10-year median of 14.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (HKMPF) is currently considered Modestly Undervalued. The stock's GF Value™ is $28.58, compared to a current price of $21.56 — trading 24.6% below its estimated fair value. The current EV-to-EBIT is 9.47, which is 34% below median its 10-year median of 14.28 and 39.1% below the Drug Manufacturers industry median of 15.55. Hikma Pharmaceuticals' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Hikma Pharmaceuticals (HKMPF), the current EV-to-EBIT is 9.47 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hikma Pharmaceuticals (HKMPF) Overvalued in 2026?
Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued.
The current stock price of $21.56 is trading 24.6% below its estimated GF Value™ of $28.58.
GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for HKMPF:
EV-to-EBIT: 9.47 (34% below median its 10-year median of 14.28)
GF Value™: $28.58 vs. price of $21.56 (24.6% below fair value)
Industry Position: 39.1% below the Drug Manufacturers median (#196 of 688)
No single metric tells the full story. See the HKMPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
82GF Score
Get the complete analysis for HKMPF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKMPF has been successfully added to your 
